Curious about the stocks that are showing activity after the closing bell on Tuesday? The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery.
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency The company is progressing with multiple Phase 2 trials for its investigational treatment targeting severe respiratory diseases.
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.
Another Trio Of Biotech IPOs Made Friday Debut The Partners Group-backed KinderCare sold 24 million shares for $24 each this past Tuesday. Meanwhile, a new trio of biotech companies' shares came to market on Friday, as Upstream Bio, CeriBell, and Camp4 Therapeutics each made their public debut.
